ExtraSuperTadarise is a compound preparation mainly containing Tadalafil and Dapoxetine. It is used for the treatment of male erectile dysfunction (ED) and premature ejaculation (PE). Due to the particularity of its compound ingredients, strict compliance with medication standards is required in clinical use.

Precautions for Administration of ExtraSuperTadarise

Contraindication Screening

Patients who are using any form of nitrates (such as nitroglycerin, isosorbide mononitrate, etc.).

Patients taking alpha-blockers (except tamsulosin 0.4mg per day).

Patients who are allergic to Tadalafil, Dapoxetine, or any excipients.

Patients with severe cardiovascular diseases (such as unstable angina pectoris, recent myocardial infarction, etc.).

Patient Assessment

Cardiovascular assessment: It is necessary to assess the patient's cardiovascular status, as sexual activity itself carries certain cardiac risks.

Liver function assessment: Patients with moderate to severe liver dysfunction need dose adjustment.

Renal function assessment: Adjust the dose according to creatinine clearance (the maximum dose for severe renal insufficiency is 5mg).

Ophthalmic examination: Use with caution in patients with a history of retinal diseases (such as retinitis pigmentosa).

Management of Drug Interactions

Nitrates: Concurrent use is absolutely contraindicated, as it may lead to life-threatening hypotension.

Potent CYP3A4 inhibitors (such as ketoconazole, ritonavir): Dose adjustment is required.

Alpha-blockers (except tamsulosin 0.4mg per day): Concurrent use is prohibited.

Alcohol: Heavy drinking may increase the risk of orthostatic hypotension.

Medication Monitoring of ExtraSuperTadarise

Routine Monitoring Items

Cardiovascular monitoring: Regular monitoring of blood pressure and heart rate.

Liver function monitoring: Regular examination of liver enzymes in patients on long-term medication.

Renal function monitoring: Regular assessment based on the patient's underlying renal function.

Monitoring of Key Adverse Reactions

Cardiovascular system: Angina pectoris, myocardial infarction, etc. (incidence < 2%).

Visual abnormalities: Color vision abnormalities, blurred vision (incidence < 0.1%).

Persistent erection: Priapism (erection lasting more than 4 hours), which is rare but requires emergency treatment.

Nervous system: Headache (15%), dizziness (2%).

Efficacy Monitoring

Erectile function: Evaluated using the IIEF (International Index of Erectile Function) questionnaire.

Ejaculatory control: Record the intravaginal ejaculatory latency time and the patient's subjective feelings.

Quality of life: Assess the overall improvement through relevant scales.